The effects of domperidone, scopolamine butylbromide and cimetidine on the absorption and bioavailability of ciprofloxacin were studied in female rats. Ciprofloxacin was given in a single oral dose of 30 mg/kg to control group. Ciprofloxacin was concurrently administered with domperidone $(T_1;group)$, scopolamine butylbromide $(T_2;group)$, and cimetidine $(T_3;group)$ to rats, respectively. Significantly changed pharmacokinetic parameters observed in $T_2$group when compared with control group were first-order absorption rate constant, $Ka(4.43{pm}0.85$;versus;2.86{pm}0.41;hr^{-1},;p<0.05)$, time needed to reach peak concentration, $T_{max};(32.27{pm}2.46;versus;51.75{pm}5.51;min,;p<0.05)$, area under the plasma concentration-time curve, AUC $(332{pm}19;versus;477{pm}27;{mu}g{cdot}min/ml,;p<0.05)$ and absolute bioavailability, Fabs $(60.6{pm}3.6;versus;87.0{pm}5.0%,;p<0.05)$. On the other hand, domperidone and cimetidine did not significantly affect the absorption of ciprofloxacin. It is suggested that when scopolamine butylbromide is selected for clinical use, there is need for awareness of the reduction in absorption rate and the enhancement in absorption extent of ciprofloxacin.